USANA Downgraded

Analysts at Ryan Beck & Co downgrade USANA Health Sciences (USNA.NAS) from “outperform” to “market perform.” The target price is set to $52.

In a research note published on January 5, the analysts mention that the downgrade in the rating is based on valuation. USANA Health Sciences remains on schedule to penetrate Malaysia as the company’s thirteenth market in 1Q07, the analysts say. There is a possibility of marginal upside to the 4Q06 and FY07 estimates on account of the recent extension of the federal research tax credit by the Congress, Ryan Beck & Co adds.

USANA Health Sciences downgraded to “market perform” | newratings.com